NEI Podcast

What are some of the biggest changes that were made to the Fifth Edition and what were the reasons behind these changes? How are mood stabilizers redefined in the Fifth Edition? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about all the updates to the Fifth Edition of Stahl’s Essential Psychopharmacology and all the exciting reasons for those updates. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology? Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology Part 3: The Future of Psychopharmacology Subscribe to the NEI Podcast, so that you don’t miss another episode!

What is unique about collaborative care, when it comes to mental health? Can you share some of the step-by -step guide to implementing the core model in clinical practice for collaborative care? In this episode, Dr. Anna Ratzliff answers these questions and much more! Dr. Anna Ratzliff is a national expert on collaborative care and specifically, on training teams to implement and deliver mental health treatment in primary care settings. Her passion for translating complex research ideas into practical real-world applications began when she received her MD and PhD in Anatomy and Neurobiology as part of the Medical Scientist Training Program at the University of California at Irvine.  She currently is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington where she has developed additional expertise in suicide prevention training, mental health workforce development, adult learning best practices, and mentorship. Dr. Ratzliff is the Director of the UW Psychiatry Resident Training Program, Co-Director of the AIMS Center (Advancing Integrated Mental Health Solutions) and Director of the UW Integrated Care Training Program for residents and fellows. Resources: AIMS Center Website: http://aims.uw.edu/ Implementation Guide: https://aims.uw.edu/collaborative-care/implementation-guide APA Training: https://www.psychiatry.org/psychiatrists/practice/professional-interests/integrated-care

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer on best practices and strategies for improving clinician and patient communication, medication adherence, and collaboration in the community when it comes to treating schizophrenia. Optional CE Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click https://nei.global/POD21-Schiz Learning Objectives: After completing this educational activity, you should be better able to: Demonstrate strategies that involve patient and caregivers in shared informed decision-making for treatment goals Discuss the role of social aspects of community and behavioral health settings on patient experiences and treatment outcomes Address best practices for the use of telemedicine when monitoring treatment for schizophrenia and the use of LAIs Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.25 continuing education hours of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Intra-Cellular, Neurocrine Speakers Bureau: Acadia, Alkermes, Intra-Cellular, Neurocrine, Noven, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck. Released: September 23, 2021          CE credit expires: September 23, 2024

Why do you feel that when it comes to psychopharmacology, knowing how to really interpret the scientific literature is important for clinicians? Why is it important to know whether the clinical characteristics of the subjects resemble or differ from your own patients and to what extent?  In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about why it is important to understand how to interpret the scientific literature and apply it to your clinical practice. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg   https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

What are the most critical components that need to be addressed about social wellbeing when it comes to children returning to school? What signs might alert parents to their children feeling anxious about returning to school? In this timely and important interview. Dr. Manpreet Singh and Dr. Jeffrey Strawn answer these questions and much more! To access the article that Dr. Singh refers to in this episode click here: https://www.nytimes.com/2021/08/20/well/family/back-to-school-fear-tip.html Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders. Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes. Dr. Jeffrey Strawn is Associate Professor in the Department of Pediatrics and in the Department of Psychiatry and Behavior Science at the University of Cincinnati, College of Medicine in Cincinnati, OH. Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents.  In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders.

What is the difference between mediators and moderators, and how do they influence treatment response? Why is it so important, as clinicians to understand the distinction between moderators and mediators and to be aware of their influence on treatment outcomes in the literature?  In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn more about how moderators and mediators influence clinical outcomes. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg    https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2

Why is it so important that many Olympic athletes are speaking out about the importance of mental health, and how can people spread more awareness for mental health concerns in this vulnerable population? What challenges do you face regarding effectively treating mental health conditions in athletes? In this important and timely interview sports psychiatrist, Dr. Greg Mattingly addresses these questions and much more! Dr. Mattingly is a physician and principal investigator in clinical trials for Midwest Research Group. He is also a founding partner of St. Charles Psychiatric Associates where he treats children, adolescents and adults. A St Louis native, he earned his medical degree and received a Fulbright scholarship while attending Washington University. Dr. Mattingly is board certified in adult and adolescent psychiatry and is a Diplomat of the National Board of Medical Examiners. He is an Associate Clinical Professor at Washington University. Dr. Mattingly has been a principal investigator in over 300 clinical trials focusing on ADHD, anxiety disorders, major depression, bipolar disorder and schizophrenia. Having served on numerous national and international advisory panels, Dr. Mattingly has received awards and distinctions for clinical leadership and neuroscience research. Dr. Mattingly currently serves on the board of directors for APSARD-The American Professional Society of ADHD and Related Disorders and is a certified evaluator for both the NFL and MLB. An avid runner and outdoorsman, Dr. Mattingly believes mind, body and spirit are important qualities for him and his family. Resources: www.Midwestresearchgroup.com

In this episode, Dr. Andrew Cutler interviews Dr. Leslie Citrome on some of the challenges that clinicians face when using traditional methods for the treatment of schizophrenia. They discuss the most current research on the development of TAAR1 agonists as a novel class of psychotropic medication for the treatment of schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD21-TAAR1  Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges with traditional methods of treating schizophrenia Discuss the development of TAAR1 agonists as new class of psychotropic medication for the treatment of schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Astellas, Avanir, Axsome, BioXcel, Cadent Therapeutics, Eisai, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Relmada, Sage, Shire, Sunovion, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Sunovion Pharmaceuticals Inc. Released: July 29, 2021 CME credit expires: July 29, 2024

How do you handle a patient who doesn’t want to talk about their suicidal thoughts? What tools and basic education strategies can we use for non-health-care professionals to highlight and prevent potential suicide/suicidal thoughts?  In this episode, Dr. Christine Moutier addressed your unanswered questions from the NEI Synapse Half Day: Before It’s Too Late: Strategies for Suicide Prevention. Dr. Moutier is the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP).  Throughout her career she has focused on fighting stigma related to mental health and help seeking. Training healthcare leaders, physicians, and advocacy groups, Dr. Moutier has sought to change the healthcare system’s approach to mental health, in order to optimize care for those suffering from mental health conditions. As a leader in the field of suicide prevention, Dr. Moutier joined AFSP in 2013, and has revitalized AFSP’s Education team, re-launched its Loss & Healing department, and expanded AFSP’s support to include those with lived experience of suicide. Moutier has authored Suicide Prevention, a Stahl's series handbook, articles and book chapters for publications such as the Journal of the American Medical Association, the Lancet, Academic Medicine, the American Journal of Psychiatry, the Journal of Clinical Psychiatry, Depression and Anxiety, and Academic Psychiatry. She has testified before the U.S. Congress and spoken at the White House, she was the host of AFSP’s documentary on surviving suicide loss, The Journey, and has appeared as an expert in The New York Times, The Washington Post, Time magazine, The Economist, The Atlantic, the BBC, NBC, CNN, and other print and television outlets. You can follow Dr. Moutier on Twitter at @cmoutierMD. For more information on the AFSP please visit: asfp.org

How does the therapeutic alliance influence treatment outcomes when it comes to treatment with placebo? What are some of the other patient characteristics that influence placebo responsivity? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Joseph Goldberg about their recent book, Practical Psychopharmacology: Translating Findings From Evidence-Based Trials Into Real-World Clinical Practice. Learn about why understanding more about placebo and nocebo effects is so important for your practice. Joseph F. Goldberg, MD, is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He is a Clinical Professor in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai, New York, NY. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently, he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. He has published over 180 original research publications in major psychiatric journals as well as several books on topics related to mood disorders. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: Placebo and Nocebo Effects in Psychopharmacology with Dr. Joseph Goldberg Part 2: Mediators and Moderators in Psychopharmacology with Dr. Joseph Goldberg Part 3: Interpreting the Literature in Psychopharmacology with Dr. Joseph Goldberg    https://www.amazon.com/Practical-Psychopharmacology-Translating-Evidence-Based-Real-World/dp/1108450741/ref=sr_1_2?dchild=1&keywords=goldberg+stahl&qid=1631810148&sr=8-2